Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer (PFE.N) on Monday won a bid in a London court to invalidate two of GSK's (GSK.L) patents relating to a respiratory syncytial virus (RSV) vaccine.
The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults.